Perspective Therapeutics, Inc.
CATXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How CATX's past catalysts played out
[203Pb]VMT-α-NET
Neuroendocrine Tumors Unresectable
[203Pb]VMT01
Recurrent Melanoma (Skin)
[203Pb]Pb-PSV359
Pancreatic Ductal Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
[203Pb]VMT-α-NET | Phase 2 | Neuroendocrine Tumors Unresectable | - | - |
[203Pb]VMT01 | Phase 2 | Recurrent Melanoma (Skin) | - | - |
[203Pb]Pb-PSV359 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Perspective Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Perspective Therapeutics, Inc.'s (CATX) pipeline across Phase 2. Its lead program is [203Pb]VMT-α-NET (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Perspective Therapeutics, Inc.'s next FDA catalyst?→
Perspective Therapeutics, Inc.'s (CATX) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CATX biotech catalysts?→
Add CATX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Perspective Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.